{"id":3988,"date":"2010-10-20T05:21:42","date_gmt":"2010-10-20T09:21:42","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3988"},"modified":"2011-07-19T17:44:45","modified_gmt":"2011-07-19T21:44:45","slug":"fda-approves-dabigatran-for-stroke-prevention-in-atrial-fibrillation","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/10\/20\/fda-approves-dabigatran-for-stroke-prevention-in-atrial-fibrillation\/","title":{"rendered":"FDA Approves Dabigatran for Stroke Prevention in Atrial Fibrillation"},"content":{"rendered":"<p><a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm230241.htm\">The FDA announced on Tuesday<\/a> that it has approved Pradaxa (dabigatran, Boehringer Ingelheim) for the prevention of stroke and blood clots in patients with atrial fibrillation. The drug will be available in 75-mg and 150-mg capsules.<\/p>\n<p>\u201cUnlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa,\u201d said Norman Stockbridge, the director of the FDA&#8217;s Division of Cardiovascular and Renal Products, in an FDA press release.<\/p>\n<p><em>Comments are closed on this post, but please join the conversation at our <a href=\"..\/dabigatran-resource-round-up\/\">Dabigatran Resource Round-Up<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA announced on Tuesday that it has approved Pradaxa (dabigatran, Boehringer Ingelheim) for the prevention of stroke and blood clots in patients with atrial fibrillation. The drug will be available in 75-mg and 150-mg capsules. \u201cUnlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa,\u201d [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,1,7],"tags":[488,339,222,342,489,368],"class_list":["post-3988","post","type-post","status-publish","format-standard","hentry","category-electrophysiology","category-general","category-prevention","tag-atrial-prevention","tag-dabigatran","tag-fda-approvals","tag-spaf","tag-stroke-prevention","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3988"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3988\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}